Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London

Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London

Phase 3 and Phase 2 Studies in APOE4/4 Alzheimer’s Patients Show Favorable Safety, Low Risk for Brain Bleed and Edema (ARIA), and Neurovascular Protection

Long-Term Phase 3 and Phase 2 Extension Data Support Precision Medicine Approach in High-Risk APOE4/4 Patients with Mild Cognitive Impairment (MCI)

Nine Posters Highlight New DTI, Volumetric MRI, and Plasma p-tau217 Findings Supporting Sustained Clinical and Brain Atrophy Benefits in MCI Patients

Valiltramiprosate Could Become First Oral Therapy to Slow Alzheimer’s Pathology